Skip to content

Continuous Ambulatory Cardiac Monitoring for Recurrent Atrial Fibrillation After Sepsis

Continuous Ambulatory Cardiac Monitoring for Recurrent Atrial Fibrillation After Sepsis

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05217485
Acronym
CAMS-AF
Enrollment
125
Registered
2022-02-01
Start date
2022-03-31
Completion date
2024-03-31
Last updated
2022-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Cardiac Arrhythmia, Infections, Sepsis

Keywords

atrial fibrillation, sepsis, anticoagulation

Brief summary

To detect atrial fibrillation after infection.

Detailed description

This study will prospectively recruit patients who are admitted to CUH general medical wards due to an infection or sepsis and develop new/first diagnosed transient AF. In CUH, our previous projects have shown that around 1500 patients are admitted under general medicine each month at least 1 new diagnosis of AF is made each day (30/month)26. In particular to the cohort that develop sepsis, they may well be frail and elderly where anticoagulation is often not prescribed as a result 27 unless definitive diagnosis of recurrent AF would be made. The CAMS-AF study will closely tie in with an already existing stroke prevention service at CUH (SOS-AF) who are already screening for patient admitted with AF on general medical wards and will therefore be able to identify those with new AF during an episode of sepsis. Potential participants will be approached by the study investigators prior to discharge and if they are in sinus rhythm written consent will be obtained to place a non-invasive wearable cardiac monitor patch for 14-days, to detect any subclinical arrhythmias, particularly AF.

Interventions

DEVICEZio 14-day cardiac patch

A wearble adhesive cardiac patch (14-day) called Zio

Sponsors

University of Cambridge
CollaboratorOTHER
Cambridge University Hospitals NHS Foundation Trust
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Interventional single arm, prospective cohort

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age \>18 * Admission with any infection or sepsis * Transient AF * Under general medicine * Can be anticoagulated or not * Sinus rhythm at discharge or point of Zio patch placement

Exclusion criteria

* Previous history of AF or paroxysmal AF * Age less than 18 years * Pregnancy * Active and known malignancy * Recent cardiac or non-cardiac surgery (3 months) * Recent myocardial infarction (3 months) * Individuals with skin allergies to plasters and adhesive devices * Chest wall deformity, skin condition over sticker site * History of thyroid disease * Current alcohol intake above recommended limits * Already has a cardiac monitor or pacemaker inserted * Known contraindication for anticoagulation therapy * Patients who lack capacity or have an estimated life expectancy \< 1 year

Design outcomes

Primary

MeasureTime frame
Quantify the incidence of early (within 14-days) AF recurrence in patients who are being discharged, following hospitalisation for an infection or sepsis and develop transient AF at CUH.12 months

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026